NAS:DNLI (USA) Also trade in: Germany

Denali Therapeutics Inc

$ 20.82 0 (0%)
Volume: 346,618 Avg Vol (1m): 348,996
Market Cap $: 1.99 Bil Enterprise Value $: 1.50 Bil
P/E (TTM): 0.00 P/B: 3.83
Earnings Power Value 0
Net Current Asset Value 3.58
Tangible Book 5.44
Projected FCF 0
Median P/S Value 642.41
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
N/A
Equity-to-Asset 0.76
Equity-to-Asset range over the past 10 years
Min: 0.76, Med: 0.85, Max: 0.88
Current: 0.76
0.76
0.88
Interest Coverage No Debt
N/A
Altman Z-Score 7.64
DISTRESS
GREY
SAFE

Profitability & Growth : 1/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -47.57
Operating Margin range over the past 10 years
Min: -47.57, Med: -35.9, Max: -35.9
Current: -47.57
-47.57
-35.9
Net Margin % -38.84
Net Margin range over the past 10 years
Min: -38.84, Med: -28.06, Max: -28.06
Current: -38.84
-38.84
-28.06
ROE % -10.09
ROE range over the past 10 years
Min: -47.46, Med: -27.31, Max: -7.16
Current: -10.09
-47.46
-7.16
ROA % -8.40
ROA range over the past 10 years
Min: -56.31, Med: -34.52, Max: -6.31
Current: -8.4
-56.31
-6.31
ROC (Joel Greenblatt) % -296.27
ROC (Joel Greenblatt) range over the past 10 years
Min: -948.81, Med: -561.87, Max: -231.37
Current: -296.27
-948.81
-231.37
3-Year Total EBITDA Growth Rate -33.00
N/A
3-Year EPS w/o NRI Growth Rate 58.80
N/A

» DNLI's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:DNLI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare LSE:GNS XMCE:ALM ROCO:4147 NAS:PTLA NYSE:XON SZSE:300294 XKRX:006280 NAS:CORT SZSE:002287 NAS:AKCA SZSE:002653 NAS:SGMO NAS:ESPR NAS:RXDX NAS:MYOK NAS:XLRN NAS:EDIT XKRX:095700 NAS:SPPI NYSE:CBM
Traded in other countries 4DN.Germany
Address 151 Oyster Point Boulevard, 2nd Floor, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle) and others.

Ratios

Current vs industry vs history
PB Ratio 3.83
PB Ratio range over the past 10 years
Min: 2.4, Med: 3.54, Max: 5.13
Current: 3.83
2.4
5.13
PS Ratio 14.80
PS Ratio range over the past 10 years
Min: 13.23, Med: 456.58, Max: 3227.14
Current: 14.8
13.23
3227.14
EV-to-EBIT -23.81
EV-to-EBIT range over the past 10 years
Min: -34.4, Med: -14.9, Max: -6.2
Current: -23.81
-34.4
-6.2
EV-to-EBITDA -27.80
EV-to-EBITDA range over the past 10 years
Min: -41, Med: -15.45, Max: -6.4
Current: -27.8
-41
-6.4
EV-to-Revenue 11.31
EV-to-Revenue range over the past 10 years
Min: 9.6, Med: 349.2, Max: 2573.8
Current: 11.31
9.6
2573.8
Current Ratio 11.55
Current Ratio range over the past 10 years
Min: 9.6, Med: 14.67, Max: 28.92
Current: 11.55
9.6
28.92
Quick Ratio 11.55
Quick Ratio range over the past 10 years
Min: 9.6, Med: 14.67, Max: 28.92
Current: 11.55
9.6
28.92
Days Sales Outstanding 20.25
Days Sales Outstanding range over the past 10 years
Min: 20.25, Med: 20.81, Max: 20.81
Current: 20.25
20.25
20.81

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -213.50
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.83
Price-to-Tangible-Book range over the past 10 years
Min: 2.9, Med: 3.51, Max: 4.43
Current: 3.83
2.9
4.43
Price-to-Median-PS-Value 0.03
Price-to-Median-PS-Value range over the past 10 years
Min: 0.03, Med: 1.23, Max: 6.02
Current: 0.03
0.03
6.02
Earnings Yield (Joel Greenblatt) % -4.19
Earnings Yield (Greenblatt) range over the past 10 years
Min: -16.1, Med: -6.7, Max: -2.9
Current: -4.19
-16.1
-2.9

More Statistics

Revenue (TTM) (Mil) $ 132.72
EPS (TTM) $ -0.59
Beta 0
Volatility % 83.34
52-Week Range $ 12.32 - 28.87
Shares Outstanding (Mil) 95.48

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N